CBL (Chemical and Biopharmaceutical Laboratories)
was founded in 1990 to provide novel chemistries in peptide synthesis.
CBL is one of the largest peptide material suppliers in the world, offering peptide starting materials, peptide intermediates, and industrial and commercial-scale manufacturing of proprietary and generic GMP and non-GMP peptides.
CBL was founded on the discovery and development of the trityl resins, including 2-chlorotrityl chloride resin. Since its establishement, CBL has maintained strong roots as a peptide technology company, demonstrating the role of technology in commerical applications.
In 1990, Prof. Barlos demonstrated the utility of the triyl resins and the hybrid process in the chemical synthesis of prothymosin, a 108 amino acid peptide (1). CBL continues to develop unique peptide reagents, such as mmt/mtt protected Fmoc-cysteine and Fmoc-lysine (2), and synthetic techniques to further enhance the commerical development of even the most complex peptides.